PBYI Financials: Puma Biotechnology Inc AI Analysis

Home

Stock

PBYI

Financials

PBYI Financial

Puma Biotechnology Inc

$6.26

0.15%

$0

At close: Mar 24, 16:00:00 GMT-4

$6.26

Post-market: Mar 24, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$6.25

Open

$6.2

Day's Range

$6.12 - $6.34

52 week range

$2.58 - $7.68

Volume

225.9K

Avg.Volume

424.9K

Dividend yield

EPS (TTM)

0.74

Market Cap

$315.4M

What is PBYI?

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 172 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm has in-licensed and is responsible for the global development and commercialization of alisertib. The company intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

PBYI Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	228	228	230	235	228	253
Revenue Growth (YoY)	-1%	-1%	-2%	3%	-10%	12%
Cost of Revenue	58	58	64	62	55	63
Gross Profit	170	170	166	172	172	189
Selling, General & Admin	70	70	80	89	90	116
Research & Development	62	62	54	50	59	71
Operating Expenses	132	132	135	139	149	188
Other Non Operating Income (Expenses)	1	1	0	0	0	0
Pretax Income	35	35	24	22	0	-28
Income Tax Expense	4	4	-6	1	0	0
Net Income	31	31	30	21	0	-29
Net Income Growth	3%	3%	43%	--	-100%	-52%
Shares Outstanding (Diluted)	51.6	50.65	49.1	47.55	44.9	40.6
Shares Change (YoY)	5%	3%	3%	6%	11%	3%
EPS (Diluted)	0.61	0.61	0.61	0.45	0	-0.72
EPS Growth	0%	0%	36%	--	-100%	-53%
Free Cash Flow	41	41	38	14	-22	20
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	74.56%	74.56%	72.17%	73.19%	75.43%	74.7%
Operating Margin	16.22%	16.22%	13.04%	14.04%	10.08%	0.39%
Profit Margin	13.59%	13.59%	13.04%	8.93%	0%	-11.46%
Free Cash Flow Margin	17.98%	17.98%	16.52%	5.95%	-9.64%	7.9%
EBITDA	47	47	41	44	31	11
EBITDA Margin	20.61%	20.61%	17.82%	18.72%	13.59%	4.34%
D&A For EBITDA	10	10	11	11	8	10
EBIT	37	37	30	33	23	1
EBIT Margin	16.22%	16.22%	13.04%	14.04%	10.08%	0.39%
Effective Tax Rate	11.42%	11.42%	-25%	4.54%	0%	0%

Follow-Up Questions

What are Puma Biotechnology Inc's key financial statements?



According to the latest financial statement (Form-10K), Puma Biotechnology Inc has a total asset of $216, Net profit of $31

What are the key financial ratios for PBYI?



Puma Biotechnology Inc's Current ratio is 2.54, has a Net margin is 13.59, sales per share of $4.5.

How is Puma Biotechnology Inc's revenue broken down by segment or geography?



Puma Biotechnology Inc largest revenue segment is Cancer Care Products, at a revenue of 230,468,000 in the most earnings release.For geography, United States is the primary market for Puma Biotechnology Inc, at a revenue of 230,468,000.

Is Puma Biotechnology Inc profitable?



yes, according to the latest financial statements, Puma Biotechnology Inc has a net profit of $31

Does Puma Biotechnology Inc have any liabilities?



yes, Puma Biotechnology Inc has liability of 85

How many outstanding shares for Puma Biotechnology Inc?



Puma Biotechnology Inc has a total outstanding shares of 50.4

Puma Biotechnology Inc (PBYI) Financial

PBYI Stock Price Chart